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LIST DO REDAKCJI / LETTER TO THE EDITOR
MGuardTM stent... We beg to differ.  
Commentary to the article “Long-term follow-up 
of mesh-covered stent implantation in patients 
with ST-segment elevation myocardial infarction”
published in “Kardiologia Polska” 2014; 72, 2: 140–145
We read with interest the article published in the Febru-
ary edition of your journal by Dudek et al. [1] about the long 
term follow up results of the mesh-covered stent (MGuardTM 
Coronary Stent System, InspireMD Ltd., Israel) in patients with 
ST elevation myocardial infarction. 
We report a higher major adverse cardiac and cerebrovas-
cular event (MACCE) complication rate in our tertiary centre 
where high volume operators perform around 1,700 percu-
taneous coronary intervention (PCI) cases/year.
In the period between July and November 2013, 
21 MGuardTM stents were deployed in 16 patients. The average 
age was 65 (range 44–85) years, with the majority (13 patients) 
being males. The average diameter stent used was 3.6 (range 
3–4) cm and average length was 22.6 (range 18–28) mm. 
Eleven cases were primary PCI, three were urgent acute 
coronary syndrome, and two were elective. Radial access 
was used in the majority of patients (ten cases). Seven cases 
involved saphenous vein grafts, six involved the right coronary 
artery, and three involved the left anterior descending artery 
(LAD). The average Thrombosis In Myocardial Infarction prior 
to the procedure was 0.7 (range 0–3). 
One case had cardiogenic shock and died shortly after 
the procedure. Fourteen cases had confirmed thrombus on 
angiography. Thrombus aspiration was used in the majority 
of cases. One case had a distal embolic protection device 
deployed. Glicoprotein IIb/IIIa inhibitors were used in four 
cases. Seven cases received predilation prior to deploying the 
MGuardTM stents and nine cases had post dilation. 
Five (31%) cases had acute PCI complication in the form 
of no reflow which resolved with intra coronary nitrates/ 
/adenosine. Three of them were in the setting of primary PCI. 
Two cases were in saphenous vein grafts of elective cases. 
Excluding the case with cardiogenic shock and death, 
13 patients had an average follow up of 79 (3–149) days. Nine 
(69%) patients experienced MACCE during the follow up pe-
riod. Six (46%) had repeat angiography. Three (23%) patients 
had definite stent thrombosis and presented with myocardial 
infarction (two were elective PCI to saphenous vein grafts 
within three and 63 days), and one within 96 days (primary 
PCI LAD). Three patients had instent restenosis (within 63, 
77 and 96 days). Three patients had target lesion revascu-
larisation: one with drug eluting stent, one with drug eluting 
balloon and one with coronary artery bypass grafting. One 
patient had cerebrovascular accident during follow up. 
We appreciate that the numbers reported here are 
small and the nature of this retrospective review carries all 
the limitations related to this type of analysis; however, our 
experience suggests that the effectiveness of the MGuardTM 
stent in the setting of a thrombus laden lesion is not entirely 
as expected, and that there is more to the pathophysiology 
than just mechanically trapping the thrombus. 
Conflict of interest: none declared
References
1. Dudek D, Dziewierz A, Kleczyński P et al. Long-term follow-up 
of mesh-covered stent implantation in patients with ST-segment 
elevation myocardial infarction. Kardiol Pol, 2014; 72: 140–145.
Ahmed Farag, Grahame Goode, Jonas Eichhöfer
Blackpool Victoria Hospital, United Kingdom
Authors’ response
We appreciate the concerns raised by Farag et al. [1] about 
our recent paper on the long-term performance of MGuardTM 
stent in patients with ST-segment elevation myocardial infarc-
tion (STEMI) undergoing primary percutaneous coronary inter-
vention (PCI) [2]. In general, it is hard to compare results of the 
MAGICAL study [2, 3] and the registry from Farag et al. [1], as 
they included different subsets of patients with different risk 
profiles. In the MAGICAL study [2, 3], consecutive, non-shock 
patients with STEMI < 12 h were enrolled. The study popula-
tion was preselected based on inclusion and exclusion criteria, 
and thus may be a lower risk group. The use of atherectomy 
and/or thrombectomy catheters and/or embolic protection 
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devices was not permitted before stent implantation in the 
MAGICAL study; thus patients with a very large thrombus 
burden and potentially the highest risk of distal embolisation 
were not included. After enrollment of 30 patients, the proto-
col of the study was changed and the use of simple aspiration 
catheters before stenting was possible at the discretion of the 
operator. Also, patients with saphenous vein grafts (SVG) ste-
nosis were not enrolled in the MAGICAL study. The long-term 
event rates were low, but were comparable to those reported 
for patients treated with a stent during primary PCI for STEMI 
[4, 5]. Importantly, all clinical events were adjudicated by an 
independent clinical events committee.
Findings from the MAGICAL study are supported by the 
results of the MASTER study [6]. This randomised, multicentre 
study reported that among patients with STEMI < 12 h, the 
MGuardTM stent resulted in superior rates of epicardial coro-
nary flow and complete ST-segment resolution compared to 
conventional metallic stents. Similarly to the MAGICAL study, 
patients with cardiogenic shock and SVG stenosis were not 
included in this study. In the MASTER study, the risk of intra-
procedural thrombotic events, defined as the development 
of new or increasing thrombus, abrupt vessel closure, no 
reflow, slow reflow, distal embolisation, side branch closure, 
or intraprocedural stent thrombosis at any time during the 
procedure for MGuardTM stent was 21.7%, but similar to that 
reported for a control group (22.3%; p = 0.83). Most impor-
tantly, a trend towards lower 30-day cardiac and all-cause 
mortality was noted for patients treated with the MGuardTM 
stent. Recently presented 12-month data [7] has confirmed 
similar trends persisting throughout a 12-month follow-up. 
Twelve-month rates of ischaemic target-lesion revascularisa-
tion in the MGuardTM group were higher than in the control 
stent group, but were comparable to those expected from 
bare-metal stents. No difference in the rate of definite or 
probable stent thrombosis was observed at 30 days (MGuardTM 
vs. control: 1.4% vs. 0.9%; p = 1.0) and at 12 months (2.3% 
vs. 0.9%; p = 0.26). These rates are far lower than those 
reported by Farag et al. [1].
In the small registry of 16 patients described by Farag et 
al. [1], MGuardTM stents were probably selected for the high-
est risk patients, when operators expected a high risk of distal 
embolisation and angiographic complications. Also, unlike the 
MAGICAL and MASTER studies, patients with SVG stenosis 
were included. It is well known that PCI of SVG stenosis carries 
an increased risk of angiographic complications, including the 
occurrence of no-reflow phenomenon [8]. Thus the events 
rate reported by Farag et al. [1] is very high, but is somewhat 
to be expected from this high risk group of patients, as the 
outcomes of patients with acute coronary syndromes are 
strongly related to baseline risk profile (i.e. presence of car-
diogenic shock/haemodynamic compromise, comorbidities) 
and angiographic characteristics (i.e. thrombus load, extent of 
coronary artery disease, SVG involvement) [9, 10]. We could 
expect similar event rates in this small and highly selected 
cohort of patients with the use of conventional bare-metal 
stents or drug-eluting stents.
Case reports, cases series, and registries all add to 
our knowledge; however, randomised clinical trials with 
head-to-head comparison are still the most appropriate tool 
for the assessment of new technologies. Data from ongoing 
randomised clinical trials, like the MASTER II trial, powered 
for clinical endpoints, is needed to weigh the competing risks 
and benefits of the MGuardTM as an alternative to metallic 
stents in patients with STEMI.
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